AstraZeneca plc Company Profile (LON:AZN)

About AstraZeneca plc (LON:AZN)

AstraZeneca plc logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: LON:AZN
  • CUSIP: N/A
  • Web: N/A
Capitalization:
  • Market Cap: £66.17 billion
  • Outstanding Shares: 1,266,000,000
Average Prices:
  • 50 Day Moving Avg: GBX 4,839.40
  • 200 Day Moving Avg: GBX 4,584.95
  • 52 Week Range: GBX 3,680 - GBX 5,505
P/E:
  • Trailing P/E Ratio: 19.58
  • P/E Growth: 3.18
Sales & Book Value:
  • Annual Revenue: £22.29 billion
  • Price / Sales: 2.97
  • Book Value: GBX 10.26 per share
  • Price / Book: 5.09
Dividend:
  • Dividend Yield: 4.2%
Profitability:
  • EBIDTA: £5.84 billion
Misc:
  • Average Volume: 2.33 million shs.
 

Frequently Asked Questions for AstraZeneca plc (LON:AZN)

What is AstraZeneca plc's stock symbol?

AstraZeneca plc trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How often does AstraZeneca plc pay dividends? What is the dividend yield for AstraZeneca plc?

AstraZeneca plc declared a dividend on Thursday, February 2nd. Stockholders of record on Thursday, February 16th will be given a dividend of GBX 150.20 per share on Monday, March 20th. This represents a dividend yield of 3.52%. The ex-dividend date of this dividend is Thursday, February 16th. This is a positive change from AstraZeneca plc's previous dividend of $68.70. The official announcement can be viewed at this link. View AstraZeneca plc's Dividend History.

When will AstraZeneca plc make its next earnings announcement?

AstraZeneca plc is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for AstraZeneca plc.

Where is AstraZeneca plc's stock going? Where will AstraZeneca plc's stock price be in 2017?

21 brokerages have issued 1 year price targets for AstraZeneca plc's stock. Their forecasts range from GBX 3,650 to GBX 6,500. On average, they anticipate AstraZeneca plc's stock price to reach GBX 5,041.80 in the next year. View Analyst Ratings for AstraZeneca plc.

Who are some of AstraZeneca plc's key competitors?

How do I buy AstraZeneca plc stock?

Shares of AstraZeneca plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How much does a share of AstraZeneca plc stock cost?

One share of AstraZeneca plc stock can currently be purchased for approximately GBX 5,227.

Analyst Ratings

Consensus Ratings for AstraZeneca plc (LON:AZN) (?)
Ratings Breakdown: 5 Sell Ratings, 7 Hold Ratings, 9 Buy Ratings
Consensus Rating:Hold (Score: 2.19)
Consensus Price Target: GBX 5,041.80

Analysts' Ratings History for AstraZeneca plc (LON:AZN)
Show:
DateFirmActionRatingPrice TargetDetails
5/26/2017InvestecBoost Price TargetHoldGBX 4,600 -> GBX 5,000View Rating Details
5/26/2017Goldman Sachs Group IncSet Price TargetSellGBX 3,900View Rating Details
5/23/2017JPMorgan Chase & Co.Reiterated RatingNeutralGBX 4,500View Rating Details
5/23/2017Liberum CapitalReiterated RatingBuyGBX 5,500View Rating Details
5/23/2017Shore CapitalReiterated RatingHoldView Rating Details
5/22/2017Deutsche Bank AGReiterated RatingBuyView Rating Details
5/20/2017Jefferies Group LLCSet Price TargetNeutralGBX 4,700View Rating Details
5/17/2017Berenberg BankBoost Price TargetBuyGBX 5,670 -> GBX 5,850View Rating Details
5/15/2017HSBC Holdings plcReiterated RatingReduceGBX 4,200View Rating Details
5/11/2017Barclays PLCReiterated RatingOverweightGBX 6,000View Rating Details
4/28/2017Sanford C. BernsteinSet Price TargetNeutralGBX 4,736View Rating Details
4/27/2017S&P GlobalSet Price TargetSellGBX 4,500View Rating Details
4/24/2017Morgan StanleyReiterated RatingBuyView Rating Details
4/21/2017Kepler Capital MarketsReiterated RatingBuyGBX 5,000View Rating Details
4/19/2017Credit Suisse Group AGReiterated RatingUnderperformGBX 4,000View Rating Details
4/3/2017BNP ParibasReiterated RatingNeutralGBX 5,300View Rating Details
4/3/2017Beaufort SecuritiesReiterated RatingHoldView Rating Details
3/23/2017Societe GeneraleReiterated RatingBuyView Rating Details
2/28/2017Bryan, Garnier & CoReiterated RatingBuyGBX 5,400View Rating Details
11/7/2016Citigroup IncReiterated RatingBuyView Rating Details
6/24/2016Independent Research GmbHSet Price TargetSellGBX 3,650View Rating Details
5/10/2016Oddo SecuritiesReiterated RatingBuyGBX 5,400View Rating Details
5/5/2016Charles StanleyUpgradeStrong-BuyView Rating Details
3/24/2016NatixisReiterated RatingNeutralGBX 4,456View Rating Details
3/23/2016NomuraLower Price TargetHoldGBX 4,880 -> GBX 4,350View Rating Details
2/12/2016Baader BankReiterated RatingHoldGBX 4,400View Rating Details
2/9/2016AlphaValueUpgradeBuyGBX 4,640View Rating Details
2/4/2016S&P Equity ResearchSet Price TargetNeutralGBX 4,500View Rating Details
2/2/2016HandelsbankenReiterated RatingAccumulateGBX 5,220.30View Rating Details
1/28/2016Pareto SecuritiesReiterated RatingSellGBX 3,855.35View Rating Details
1/27/2016SwedbankReiterated RatingBuyGBX 5,115.47View Rating Details
1/13/2016Nordea Equity ResearchReiterated RatingHoldGBX 4,698.35View Rating Details
7/14/2015DanskeUpgradeHoldGBX 4,400View Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for AstraZeneca plc (LON:AZN)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for AstraZeneca plc (LON:AZN)
Current Year EPS Consensus Estimate: $3.73 EPS

Dividends

Dividend History by Quarter for AstraZeneca plc (LON:AZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/2/2017GBX 150.203.52%2/16/20172/16/20173/20/2017
7/28/2016GBX 68.701.37%8/11/20168/11/20169/12/2016
2/4/2016GBX 1313.16%2/18/20162/18/20163/21/2016
7/30/2015GBX 57.501.33%8/13/20158/13/20159/14/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for AstraZeneca plc (LON:AZN)
Insider Trades by Quarter for AstraZeneca plc (LON:AZN)
Insider Trades by Quarter for AstraZeneca plc (LON:AZN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/27/2015Courtois,Jean-PhilippeInsiderBuy900GBX 4,423£39,807
8/28/2015Soriot,PascalInsiderBuy76,300GBX 3,960£3,021,480
5/7/2015Marc DunoyerInsiderBuy10,000GBX 4,397£439,700
4/30/2015Ann CairnsInsiderBuy1,100GBX 4,455£49,005
4/29/2015Shriti VaderaInsiderBuy3,500GBX 4,563£159,705
4/28/2015Graham ChipchaseInsiderBuy1,100GBX 4,606£50,666
4/27/2015Bruce BurlingtonInsiderBuy600GBX 4,662£27,972
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for AstraZeneca plc (LON:AZN)
Latest Headlines for AstraZeneca plc (LON:AZN)
Source:
DateHeadline
americanbankingnews.com logoAstraZeneca plc (AZN) Given a GBX 3,900 Price Target by Goldman Sachs Group Inc Analysts
www.americanbankingnews.com - May 26 at 11:02 PM
americanbankingnews.com logoAstraZeneca plc (AZN) PT Raised to GBX 5,000 at Investec
www.americanbankingnews.com - May 26 at 7:14 AM
nasdaq.com logoAstraZeneca Recalls One Lot Of BRILINTA 90mg Professional Sample Bottles - Nasdaq
www.nasdaq.com - May 25 at 9:42 PM
finance.yahoo.com logoAstraZeneca Sells Marketing Rights to Seloken in Europe
finance.yahoo.com - May 23 at 3:51 PM
finance.yahoo.com logoNovo Nordisk Diabetes Lead Unscathed Following AstraZeneca Trial
finance.yahoo.com - May 23 at 3:51 PM
americanbankingnews.com logoDeutsche Bank AG Reiterates "Buy" Rating for AstraZeneca plc (AZN)
www.americanbankingnews.com - May 22 at 7:00 PM
finance.yahoo.com logo[$$] AstraZeneca sells Seloken European rights for $300m
finance.yahoo.com - May 22 at 3:46 PM
finance.yahoo.com logoSevere asthma drug shows AstraZeneca promise beyond cancer
finance.yahoo.com - May 22 at 3:46 PM
nasdaq.com logoAstraZeneca, Recordati Enter Deal For Seloken; AstraZeneca To Receive $300 Mln
www.nasdaq.com - May 22 at 10:20 AM
americanbankingnews.com logoAstraZeneca plc (AZN) Given a GBX 4,700 Price Target at Jefferies Group LLC
www.americanbankingnews.com - May 21 at 4:20 PM
finance.yahoo.com logo[$$] Biotech Investor Clarus Ventures Raising $880 Million Fund
finance.yahoo.com - May 19 at 9:19 AM
americanbankingnews.com logoBerenberg Bank Increases AstraZeneca plc (AZN) Price Target to GBX 5,850
www.americanbankingnews.com - May 19 at 12:08 AM
msn.com logoAstraZeneca PLC 'one for the brave', but still a 'buy', according to leading City broker
www.msn.com - May 17 at 12:07 PM
finance.yahoo.com logoAstraZeneca Plc – Value Analysis (LONDON:AZN) : May 16, 2017
finance.yahoo.com - May 16 at 3:52 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Upgraded at Shore Capital
www.americanbankingnews.com - May 16 at 12:20 PM
americanbankingnews.com logoJPMorgan Chase & Co. Reiterates Neutral Rating for AstraZeneca plc (AZN)
www.americanbankingnews.com - May 14 at 12:08 PM
americanbankingnews.com logoJefferies Group LLC Lowers AstraZeneca plc (AZN) Price Target to GBX 4,700
www.americanbankingnews.com - May 13 at 2:05 PM
nasdaq.com logoAstraZeneca, MedImmune Report Positive Results For Imfinzi Trial In NSCLC
www.nasdaq.com - May 12 at 9:20 PM
seekingalpha.com logoAstraZeneca Group plc (AZN)
seekingalpha.com - May 12 at 4:20 PM
finance.yahoo.com logoAstraZeneca Shows That With Immune Cancer Drugs, No One Knows What's Next
finance.yahoo.com - May 12 at 4:20 PM
finance.yahoo.com logoFTSE 100 closes at an all-time high as AstraZeneca rallies, pound stalls
finance.yahoo.com - May 12 at 4:20 PM
finance.yahoo.com logoIs AstraZeneca The Next Big Player In Cancer Immunotherapies?
finance.yahoo.com - May 12 at 4:20 PM
finance.yahoo.com logoAstraZeneca Shares Jump On Cancer Trial That Rivals Dow's Merck
finance.yahoo.com - May 12 at 4:20 PM
seekingalpha.com logoAstraZeneca's tralokinumab flunks late-stage asthma study - Seeking Alpha
seekingalpha.com - May 10 at 11:57 PM
americanbankingnews.com logoShore Capital Reiterates "Sell" Rating for AstraZeneca plc (AZN)
www.americanbankingnews.com - May 10 at 12:33 PM
seekingalpha.com logoAstraZeneca's New Drug: Too Little, Too Late? - Seeking Alpha
seekingalpha.com - May 8 at 10:42 AM
finance.yahoo.com logoPharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit
finance.yahoo.com - May 8 at 10:42 AM
americanbankingnews.com logoAstraZeneca plc's (AZN) "Overweight" Rating Reaffirmed at Barclays PLC
www.americanbankingnews.com - May 7 at 8:55 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Rating Reiterated by Shore Capital
www.americanbankingnews.com - May 7 at 4:02 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Earns "Reduce" Rating from HSBC Holdings plc
www.americanbankingnews.com - May 6 at 10:34 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 3 at 10:06 AM
americanbankingnews.com logoAstraZeneca plc (AZN) Given Hold Rating at Jefferies Group LLC
www.americanbankingnews.com - April 30 at 7:58 PM
americanbankingnews.com logoAstraZeneca plc's (AZN) "Buy" Rating Reiterated at Liberum Capital
www.americanbankingnews.com - April 30 at 6:54 PM
finance.yahoo.com logo[$$] Pearson defends CEO pay ahead of investor showdown
finance.yahoo.com - April 30 at 5:04 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Stock Rating Reaffirmed by Shore Capital
www.americanbankingnews.com - April 30 at 3:47 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Stock Rating Reaffirmed by Investec
www.americanbankingnews.com - April 30 at 11:28 AM
americanbankingnews.com logoAstraZeneca plc (AZN) Given New GBX 5,350 Price Target at Deutsche Bank AG
www.americanbankingnews.com - April 30 at 9:56 AM
americanbankingnews.com logoAstraZeneca plc (AZN) Rating Reiterated by Barclays PLC
www.americanbankingnews.com - April 30 at 9:23 AM
americanbankingnews.com logoAstraZeneca plc (AZN) Price Target Cut to GBX 4,200 by Analysts at HSBC Holdings plc
www.americanbankingnews.com - April 30 at 9:22 AM
americanbankingnews.com logoJPMorgan Chase & Co. Increases AstraZeneca plc (AZN) Price Target to GBX 4,500
www.americanbankingnews.com - April 30 at 6:22 AM
americanbankingnews.com logoAstraZeneca plc (AZN) Given a GBX 4,500 Price Target at S&P Global
www.americanbankingnews.com - April 28 at 8:56 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Given a GBX 5,670 Price Target at Berenberg Bank
www.americanbankingnews.com - April 28 at 8:56 PM
americanbankingnews.com logoAstraZeneca plc's (AZN) Hold Rating Reaffirmed at Investec
www.americanbankingnews.com - April 28 at 8:54 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Given "Sell" Rating at Shore Capital
www.americanbankingnews.com - April 28 at 8:54 PM
americanbankingnews.com logoAstraZeneca plc (AZN) Given Buy Rating at Liberum Capital
www.americanbankingnews.com - April 28 at 7:12 PM
americanbankingnews.com logoAstraZeneca plc's (AZN) "Hold" Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - April 28 at 7:04 PM
finance.yahoo.com logoEdited Transcript of AZN.L earnings conference call or presentation 27-Apr-17 11:00am GMT
finance.yahoo.com - April 28 at 4:44 PM
finance.yahoo.com logoAstraZeneca (AZN) Q1 Earnings Beat, Revenues Meet Estimates
finance.yahoo.com - April 28 at 4:44 PM
finance.yahoo.com logo[$$] Biotech and big pharma reap rewards from partnerships
finance.yahoo.com - April 28 at 4:44 PM
americanbankingnews.com logoSanford C. Bernstein Analysts Give AstraZeneca plc (AZN) a GBX 4,736 Price Target
www.americanbankingnews.com - April 28 at 6:38 AM

Social

Social activity is not available for this stock.

Chart

AstraZeneca plc (AZN) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff